Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Staskin

Showing results (31-40 of 54) with videos related to

Pageof 6
Sort By:
European Urology|November 18, 2019
Efficacy, safety, and tolerability of mirabegron in patients aged ≥65yr with overactive bladder wet: a phase IV, double-blind, randomised, placebo-controlled study (PILLAR)Adrian Wagg, David Staskin, Eli Engel, et al.
Current Medical Research and Opinion|February 4, 2010
Efficacy of fesoterodine over 24 hours in subjects with overactive bladderDavid Staskin, Martin C Michel, Victor Nitti, et al.
World Journal of Urology|September 10, 2005
Transdermal oxybutynin in the treatment of adults with overactive bladder: combined results of two randomized clinical trialsRoger R Dmochowski, Victor Nitti, David Staskin, et al.
Urology|September 3, 2025
Clinically Meaningful Improvements With Vibegron in Men With Overactive Bladder and Benign Prostatic Hyperplasia: A Responder Analysis of the Phase 3 COURAGE TrialKenneth M Peters, Janet Owens-Grillo, Elizabeth Thomas, et al.
Therapeutics and Clinical Risk Management|March 10, 2022
An Evaluation of the Efficacy and Safety of Vibegron in the Treatment of Overactive BladderJeffrey Frankel, David Staskin, Susann Varano, et al.
Journal of Comparative Effectiveness Research|August 16, 2023
Plain language summary: does treatment with vibegron result in improvements in overactive bladder (OAB) symptoms that are meaningful to people with OAB?Jeffrey Frankel, David Staskin, Susann Varano, et al.
Journal of the American Geriatrics Society|October 15, 2010
Trospium chloride is undetectable in the older human central nervous systemDavid Staskin, Gary Kay, Cara Tannenbaum, et al.
Neurourology and Urodynamics|May 12, 2011
Effects of voluntary dose escalation in a placebo-controlled, flexible-dose trial of fesoterodine in subjects with overactive bladderDavid Staskin, Vik Khullar, Martin C Michel, et al.
Health and Quality of Life Outcomes|April 21, 2018
Patient-reported outcomes in patients with overactive bladder treated with mirabegron and tolterodine in a prospective, double-blind, randomized, two-period crossover, multicenter study (PREFER)Sender Herschorn, David Staskin, Le Mai Tu, et al.
BMC Geriatrics|March 19, 2020
Effect of mirabegron on cognitive function in elderly patients with overactive bladder: MoCA results from a phase 4 randomized, placebo-controlled study (PILLAR)Tomas L Griebling, Noll L Campbell, Jeffrey Mangel, et al.
Pageof 6

Showing results (31-40 of 54) with videos related to

Sort By:
Pageof 6
European Urology|November 18, 2019
Efficacy, safety, and tolerability of mirabegron in patients aged ≥65yr with overactive bladder wet: a phase IV, double-blind, randomised, placebo-controlled study (PILLAR)Adrian Wagg, David Staskin, Eli Engel, et al.
Current Medical Research and Opinion|February 4, 2010
Efficacy of fesoterodine over 24 hours in subjects with overactive bladderDavid Staskin, Martin C Michel, Victor Nitti, et al.
World Journal of Urology|September 10, 2005
Transdermal oxybutynin in the treatment of adults with overactive bladder: combined results of two randomized clinical trialsRoger R Dmochowski, Victor Nitti, David Staskin, et al.
Urology|September 3, 2025
Clinically Meaningful Improvements With Vibegron in Men With Overactive Bladder and Benign Prostatic Hyperplasia: A Responder Analysis of the Phase 3 COURAGE TrialKenneth M Peters, Janet Owens-Grillo, Elizabeth Thomas, et al.
Therapeutics and Clinical Risk Management|March 10, 2022
An Evaluation of the Efficacy and Safety of Vibegron in the Treatment of Overactive BladderJeffrey Frankel, David Staskin, Susann Varano, et al.
Journal of Comparative Effectiveness Research|August 16, 2023
Plain language summary: does treatment with vibegron result in improvements in overactive bladder (OAB) symptoms that are meaningful to people with OAB?Jeffrey Frankel, David Staskin, Susann Varano, et al.
Journal of the American Geriatrics Society|October 15, 2010
Trospium chloride is undetectable in the older human central nervous systemDavid Staskin, Gary Kay, Cara Tannenbaum, et al.
Neurourology and Urodynamics|May 12, 2011
Effects of voluntary dose escalation in a placebo-controlled, flexible-dose trial of fesoterodine in subjects with overactive bladderDavid Staskin, Vik Khullar, Martin C Michel, et al.
Health and Quality of Life Outcomes|April 21, 2018
Patient-reported outcomes in patients with overactive bladder treated with mirabegron and tolterodine in a prospective, double-blind, randomized, two-period crossover, multicenter study (PREFER)Sender Herschorn, David Staskin, Le Mai Tu, et al.
BMC Geriatrics|March 19, 2020
Effect of mirabegron on cognitive function in elderly patients with overactive bladder: MoCA results from a phase 4 randomized, placebo-controlled study (PILLAR)Tomas L Griebling, Noll L Campbell, Jeffrey Mangel, et al.
Pageof 6